ReviewWiener medizinische Wochenschrift (1946)2014
Pyoderma gangrenosum: pathogenetic oriented treatment approaches.
Review in Wiener medizinische Wochenschrift (1946), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review.Clinical rheumatology · 2021Pooled it
- Selective IL-23 Inhibition in Conventional Treatment-Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study.International journal of dermatology · 2026Article
- Cutaneous Manifestations of Primary Sjögren's Syndrome: Pyoderma Gangrenosum as a Rare Initial Presentation - A Case Report and Literature Review.Annals of African medicine · 2026Review
- Pyoderma gangrenosum, as the first clinical presentation of systemic lupus erythematous, a case report and comprehensive literature review.Caspian journal of internal medicine · 2025Article
- [Current situation and the latest progress in the treatment of pyoderma gangrenosum].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2022Article
- Multifocal Pyoderma Gangrenosum with an Underlying Hemophagocytic Lymphohistiocytosis: Case Report and the Review of the Literature.Dermatology and therapy · 2021Review
- [Anakinra therapy in a patient with multifocal pyoderma gangrenosum and hidradenitis suppurativa].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021Article
- Pyoderma gangrenosum-like lesion secondary to methylenetetrahydrofolate reductase mutation: an unusual presentation of a rare disease.BMJ case reports · 2019Article
- A Comprehensive Review of Neutrophilic Diseases.Clinical reviews in allergy & immunology · 2018Review
- Refractory skin lesion, hypertension, and acute kidney injury in a young boy: Answers.Pediatric nephrology (Berlin, Germany) · 2017Article
- Pyoderma gangrenosum-a novel approach?Wiener medizinische Wochenschrift (1946) · 2017Review
- Pyoderma gangrenosum with spleen involvement. Review of the literature and case report.Journal of dermatological case reports · 2016Article
- Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case.International medical case reports journal · 2016Article
- Use of Becaplermin for nondiabetic ulcers: pyoderma gangrenosum and calciphylaxis.Dermatologic therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyoderma gangrenosum (PG) shows features of autoimmune and autoinflammatory disorders. Genetic defects which affect the inflammasome, and in particular the NLRP3 zone, can cause an abnormal secretion of interleukin 1 (IL-1). IL-1 may be involved in clinical manifestation of certain (genetic) forms of PG. IL-1 receptor antagonists reduce the activity of IL-1α and IL-1β. Mutations in the PSTPIP1 gene have been identified in patients with pyogenic arthritis, pyoderma gangrenosum and acne syndrome. In patients with a pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome these mutations cannot be found and the effect of IL-1 inhibition is questionable. Another upcoming opportunity is targeted therapy by tumor necrosis factor-alfa inhibitors in steroid-resistant patients. This review has been focused on (1) the modern pathogenetic concepts, (2) the currently accepted criteria for differentiating the disease, (3) the target therapy and (4) valuable advice to the clinicians regarding a number of medicaments capable of aggravating or inducing the PG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.